Nexalin Wins 400-15 House Vote to Back $945M VA DIFS TBI Research
The U.S. House approved FY2027 VA Appropriations report language by a 400-15 vote directing $945M VA Medical Research to support additional non-invasive deep brain neurostimulation studies for treatment-resistant TBI. Championed by Nexalin America, this directive aligns with Nexalin’s UC San Diego clinical research program using its DIFS waveform.
1. Congressional Approval of VA Research Directive
The U.S. House approved the FY2027 Military Construction, Veterans Affairs, and Related Agencies Appropriations bill report language by a 400-15 vote, directing the VA to allocate portions of its $945 million medical research budget to additional studies of non-invasive deep brain neurostimulation for treatment-resistant TBI. This directive marks the second Congressional action this year recognizing emerging non-invasive deep brain neurostimulation therapies for veterans and is expected to proceed through a House-Senate conference before final enactment.
2. Alignment with Nexalin’s Research and Technology
Nexalin America led advocacy for the report language and believes its proprietary DIFS waveform meets the directive’s criteria for penetrating deep brain structures associated with TBI and PTSD. The directive complements Nexalin’s ongoing clinical study at UC San Diego evaluating the safety and efficacy of DIFS deep brain neurostimulation, potentially paving the way for expanded institutional support and future integration of Nexalin’s technology at the VA.